A comparison of two phase I trial designs

Area of Science:

• Oncology
• Biostatistics
• Clinical Trial Design

Background:

• Phase I cancer chemotherapy trials aim to identify the maximum tolerated dose (MTD) of novel agents.
• The continual reassessment method (CRM) is a Bayesian approach proposed to enhance traditional trial designs.
• Previous comparisons of CRM and standard designs may not fully reflect practical application scenarios.

Purpose of the Study:

• To compare the practical performance of the continual reassessment method against standard designs in Phase I cancer trials.
• To evaluate the impact of CRM on patient dosing and trial duration.
• To propose enhancements for both standard and Bayesian trial designs.

Main Methods:

• Comparative analysis of clinical trial designs.
• Simulation or retrospective analysis of patient dosing and trial timelines under different designs.
• Development of methodological improvements for trial design optimization.

Main Results:

• The continual reassessment method resulted in a higher proportion of patients receiving doses at the very high end of the tested range.
• Trials employing the continual reassessment method tended to require longer completion times compared to standard designs.
• Identified limitations in previous comparative studies of CRM.

Conclusions:

• The practical implementation of the continual reassessment method may lead to increased patient exposure to potentially toxic high doses.
• The efficiency of the continual reassessment method in terms of trial duration requires careful consideration.
• Suggested improvements aim to refine both standard and Bayesian approaches for Phase I cancer trials.